Posted 29th December 2017 by Jane Williams
Honey Reddi, Clinical Laboratory Director at the Jackson Laboratory spoke at the 4th Global Precision Medicine and Biomarkers Leader Summit. She gives us an insight on liquid biopsies in the clinic and the effectiveness of current treatment.
Posted 11th December 2017 by Jane Williams
It is that time of the year to celebrate the most significant breakthroughs and accomplishments in the field of digital pathology. 2017 has been an exciting year with Philips receiving FDA approval to market their IntelliSite Pathology Solution for primary diagnostic use in the US.
Posted 20th November 2017 by Jane Williams
Recent step change advances in sequencing technologies have delivered a near-complete lexicon of genomic cancer drivers. In parallel, progress in synthetic chemistry has facilitated the assembly of a broad armamentarium of molecularly-targeted therapies. However, whilst immunotherapy agents have produced notable benefits for subgroups of patients, the impact of molecularly-targeted therapies have been relatively modest.
Further unlocking the undeniable power of genomics in cancer will involve both the systematic removal of barriers and the avoidance of distractions that obscure progress. Both of which are discussed here.
Posted 25th October 2017 by Jane Williams
Presented at the 4th Global Precision Medicine & Biomarkers Leader Summit, these slides are now available to download and share with your colleagues.
Posted 15th September 2017 by Jane Williams
In 2017, technological advances in cloud computing and artificial intelligence has pathology positioned to become one of the most talked about medical fields in healthcare.
Posted 11th September 2017 by Jane Williams
Non-invasive evaluation of molecular markers has shifted from the realm of prenatal diagnosis to tracking the effect of cancer treatment and management.
Posted 25th August 2017 by Jane Williams
Rheumatoid arthritis is one of the highest sources of the inefficiency of worldwide health care systems. This could be avoided by more tailored and individualised therapeutic strategies which require better molecular characterization of each patient.
Posted 7th August 2017 by Jane Williams
At the dawn of the last century, people who were heralded as world-changers were a different breed. Edison, Franklin (and let’s also put Tesla here, though his contributions weren’t recognized at the time), Turing, Neumann, and a lot of other great people. Things are different now. The people we idolize today are the innovators – Jobs, Musk, Page&Brin – the Great Communicators who can drive products to the market, and carve out a viable market strategy despite the strong competition, or create entirely new markets.